1887

Abstract

is an ESKAPE pathogen and threatens human health by generating infections with high fatality rates. leads to a spectrum of infections such as skin and wound infections, endocarditis, meningitis pneumonia, septicaemia and urinary tract infections. Recently, strains of have emerged as multidrug-resistant (MDR), meaning they are resistant to at least three different classes of antibiotics. MDR development is primarily intensified by widespread antibiotic misuse and inadequate stewardship. The World Health Organization (WHO) declared a precarious MDR species. maintains the MDR phenotype via a diverse array of antimicrobial metabolite-hydrolysing enzymes, efflux of antibiotics, impermeability and antibiotic target modification, thereby complicating treatment. Hence, a deeper understanding of the resistance mechanisms employed by MDR can give possible approaches to treat antimicrobial resistance. Resistance-nodulation-cell division (RND) efflux pumps have been identified as the key contributors to MDR determinants, owing to their capacity to force a broad spectrum of chemical substances out of the bacterial cell. Though synthetic inhibitors have been reported previously, their efficacy and safety are of debate. As resistance-modifying agents, phytochemicals are ideal choices. These natural compounds could eliminate the bacteria or interact with pathogenicity events and reduce the bacteria’s ability to evolve resistance. This review aims to highlight the mechanism behind the multidrug resistance in and elucidate the utility of natural compounds as efflux pump inhibitors to deal with the infections caused by .

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001867
2024-08-30
2024-11-05
Loading full text...

Full text loading...

References

  1. Osman A-H, Kotey FCN, Odoom A, Darkwah S, Yeboah RK et al. The potential of bacteriophage-antibiotic combination therapy in treating infections with multidrug-resistant bacteria. Antibiotics 2023; 12:1329 [View Article] [PubMed]
    [Google Scholar]
  2. Pilmis B, Weiss E, Scemla A, Le Monnier A, Grossi PA et al. Multidrug-resistant Enterobacterales infections in abdominal solid organ transplantation. Clin Microbiol Infect 2023; 29:38–43 [View Article] [PubMed]
    [Google Scholar]
  3. Leão PVS, Ferreira ALDS, Oliveira FADA, Mesquita ABDS, Lima-Net JDS et al. Riparin-B as a potential inhibitor of AdeABC efflux system from Acinetobacter baumannii. Evid Based Complement Alternat Med 2023; 2023:1780838 [View Article] [PubMed]
    [Google Scholar]
  4. Jampilek J, Kraova K. Mycosynthesis of metal-based nanoparticles and their perspectives in agri-food and veterinary/medical applications. In In Fungal Cell Factories for Sustainable Nanomaterials Productions and Agricultural Applications Elsevier; 2023 pp 423–482 [View Article]
    [Google Scholar]
  5. Banerjee T, Mishra A, Das A, Sharma S, Barman H et al. High prevalence and endemicity of multidrug resistant Acinetobacter spp. J Pathog 20189129083 [View Article]
    [Google Scholar]
  6. Mirzaei B, Bazgir ZN, Goli HR, Iranpour F, Mohammadi F et al. Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran. BMC Res Notes 2020; 13:1–6 [View Article] [PubMed]
    [Google Scholar]
  7. Rangel K, Chagas TPG, De-Simone SG. Acinetobacter baumannii infections in times of COVID-19 pandemic. J Pathogens 2021; 10:1006 [View Article]
    [Google Scholar]
  8. Abdallah EM, Abdalla RM. Acinetobacter baumannii, a global health-threatening bacterium: a short review. J Microbiol Exp 2021; 6:181–184 [View Article]
    [Google Scholar]
  9. Abed AB, Korcan SE, Güngör S. Antibiotics profile map of clinical A. baumannii strains isolated from health institutions in Turkey: a database search study and analysis of publications from 2011 to 2022. Bull Natl Res Cent 2023; 47:1–29 [View Article]
    [Google Scholar]
  10. Mufti IU, Gondal A, Kiyani KM, Mufti SM, Shahid R et al. Microstructural, physico-chemical, antibacterial and antibiofilm efficacy of imipenem loaded chitosan nano-carrier systems to eradicate multidrug resistant Acinetobacter baumannii. Mater Today Commun 2023; 35:105874 [View Article]
    [Google Scholar]
  11. Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol 2018; 16:91–102 [View Article] [PubMed]
    [Google Scholar]
  12. Gontijo AVL, Pereira SL, de Lacerda Bonfante H. Can drug repurposing be effective against carbapenem-resistant Acinetobacter baumannii?. Curr Microbiol 2022; 79:1–12 [View Article]
    [Google Scholar]
  13. Rose S, Shamanna V, Underwood A, Nagaraj G, Prasanna A et al. Molecular dissection of carbapenem-resistant Acinetobacter baumannii? circulating in Indian hospitals using whole genome sequencing. bioRxiv 2021 [View Article]
    [Google Scholar]
  14. An JH, Kim Y-H, Moon J-E, Jeong JH, Kim S-H et al. Active surveillance for carbapenem-resistant Acinetobacter baumannii in a medical intensive care unit: can it predict and reduce subsequent infections and the use of colistin?. Am J Infect Control 2017; 45:667–672 [View Article] [PubMed]
    [Google Scholar]
  15. Poirel L, Bonnin RA, Boulanger A, Schrenzel J, Kaase M et al. Tn125-related acquisition of blandm-like genes in Acinetobacter baumannii. Antimicrob Agents Chemother 2012; 56:1087–1089 [View Article]
    [Google Scholar]
  16. Shrestha S, Tada T, Miyoshi-Akiyama T, Ohara H, Shimada K et al. Molecular epidemiology of multidrug-resistant Acinetobacter baumannii isolates in a university hospital in Nepal reveals the emergence of a novel epidemic clonal lineage. Int J Antimicrob Agents 2015; 46:526–531 [View Article]
    [Google Scholar]
  17. Mathlouthi N, El Salabi AA, Ben Jomàa-Jemili M, Bakour S, Al-Bayssari C et al. Early detection of metallo-β-lactamase NDM-1- and OXA-23 carbapenemase-producing Acinetobacter baumannii in Libyan hospitals. Int J Antimicrob Agents 2016; 48:46–50 [View Article] [PubMed]
    [Google Scholar]
  18. Zaidan N, Hornak JP, Reynoso D. Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination. Antimicrob Agents Chemother 2021; 65:e0092421 [View Article] [PubMed]
    [Google Scholar]
  19. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother 2018; 73:22–32 [View Article] [PubMed]
    [Google Scholar]
  20. Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important Acinetobacter spp.: an update. Future Sci 2019; 25:FSO395 [View Article] [PubMed]
    [Google Scholar]
  21. Abdi SN, Ghotaslou R, Ganbarov K, Mobed A, Tanomand A et al. Acinetobacter baumannii efflux pumps and antibiotic resistance. Infect Drug Resist 2020423–434
    [Google Scholar]
  22. Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist 2020; 21:1249–1260 [View Article] [PubMed]
    [Google Scholar]
  23. Qi L, Li H, Zhang C, Liang B, Li J et al. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Front Microbiol 2016; 7:483 [View Article] [PubMed]
    [Google Scholar]
  24. Castillo-Ramírez S. The importance of Acinetobacter baumannii from non-human sources. Lancet Microbe 2023; 4:e761–e762 [View Article]
    [Google Scholar]
  25. Machado-Moreira B, Richards K, Brennan F, Abram F, Burgess CM. Microbial contamination of fresh produce: what, where, and how?. Compr Rev Food Sci Food Saf 2019; 18:1727–1750 [View Article] [PubMed]
    [Google Scholar]
  26. Ababneh Q, Abulaila S, Jaradat Z. Isolation of extensively drug resistant Acinetobacter baumannii from environmental surfaces inside intensive care units. Am J Infect Control 2023; 11:e14709 [View Article]
    [Google Scholar]
  27. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2018; 21:538–582 [View Article]
    [Google Scholar]
  28. Chilam J, Argimón S, Limas MT, Masim ML, Gayeta JM et al. Philippines antimicrobial resistance surveillance program. Genomic surveillance of Acinetobacter baumannii in the Philippines, 2013-2014. Western Pac Surveill Response J 2021; 27:1–15
    [Google Scholar]
  29. Thirapanmethee K, Srisiri-A-Nun T, Houngsaitong J, Montakantikul P, Khuntayaporn P et al. Prevalence of OXA-type β-lactamase genes among carbapenem-resistant Acinetobacter baumannii clinical isolates in Thailand. Antibiotics 2020; 9:864 [View Article] [PubMed]
    [Google Scholar]
  30. Kuo SC, Huang WC, Huang TW, Wang HY, Lai JF et al. Molecular epidemiology of emerging blaoxa-23-like- and blaoxa-24-like-carrying Acinetobacter baumannii in Taiwan. Antimicrob Agents Chemother 2018; 62:e01215–17 [View Article]
    [Google Scholar]
  31. Poirel L, Nordmann P. Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-58 in Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50:1442–1448 [View Article] [PubMed]
    [Google Scholar]
  32. Suárez CJ, Lolans K, Villegas MV, Quinn JP. Mechanisms of resistance to beta-lactams in some common gram-negative bacteria causing nosocomial infections. Expert Rev Anti Infect Ther 2005; 3:915–922 [View Article] [PubMed]
    [Google Scholar]
  33. Fursova NK, Fursov MV, Astashkin EI, Fursova AD, Novikova TS et al. Multidrug-resistant and extensively drug-resistant Acinetobacter baumannii causing nosocomial meningitis in the neurological intensive care unit. Microorganisms 2023; 11:2020 [View Article]
    [Google Scholar]
  34. Greene C, Vadlamudi G, Newton D, Foxman B, Xi C. The influence of biofilm formation and multidrug resistance on environmental survival of clinical and environmental isolates of Acinetobacter baumannii. Am J Infect Control 2016; 44:e65–71 [View Article] [PubMed]
    [Google Scholar]
  35. Cavallo I, Oliva A, Pages R, Sivori F, Truglio M et al. Acinetobacter baumannii in the critically ill: complex infections get complicated. Front Microbiol 2023; 14:1196774 [View Article] [PubMed]
    [Google Scholar]
  36. Piletić K, Kovač B, Planinić M, Vasiljev V, Karačonji IB et al. Combined biocidal effect of gaseous ozone and citric acid on Acinetobacter baumannii biofilm formed on ceramic tiles and polystyrene as a novel approach for infection prevention and control. Processes 2022; 10:1788 [View Article]
    [Google Scholar]
  37. Ababneh Q, Abulaila S, Jaradat Z. Isolation of extensively drug resistant Acinetobacter baumannii from environmental surfaces inside intensive care units. Am J Infect Control 2023; 25:11 [View Article]
    [Google Scholar]
  38. Diao J, Li S, Ma L, Zhang P, Bai J et al. Genome-wide analysis of major facilitator superfamily and its expression in response of poplar to Fusarium oxysporum. Front Genet 2021; 12:769888 [View Article] [PubMed]
    [Google Scholar]
  39. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. . Nat Rev Microbiol 2007; 5:939–951 [View Article] [PubMed]
    [Google Scholar]
  40. Alrahmany D, Omar AF, Harb G, El Nekidy WS, Ghazi IM. Infections in hospitalized patients, Treatment outcomes. Antibiot 2021; 10:630 [View Article]
    [Google Scholar]
  41. Hartzell JD, Kim AS, Kortepeter MG, Moran KA. Acinetobacter pneumonia: a review. MedGenMed Jul 2007; 5:
    [Google Scholar]
  42. Ebringer A, Rashid T, Wilson C. Multiple sclerosis and creutzfeldt–jakob disease are autoimmune diseases probably caused by exposure to the nasal microbe Acinetobacter in infection and autoimmunity. Ann N Y Acad Sci 2015505–517 [View Article]
    [Google Scholar]
  43. Suresh S, Aditya V, Deekshit VK, Manipura R, Premanath R. A rare occurrence of multidrug-resistant environmental Acinetobacter baumannii strains from the soil of Mangaluru, India. Arch Microbiol 2022; 204:422 [View Article] [PubMed]
    [Google Scholar]
  44. Thomas R, Wadula J, Seetharam S, Velaphi S. Prevalence, antimicrobial susceptibility profiles and case fatality rates of Acinetobacter Baumannii sepsis in a neonatal unit. J Infect Dev Ctries 2018; 12:211–219 [View Article] [PubMed]
    [Google Scholar]
  45. Al Jarousha AMK, El Jadba AHN, Al Afifi AS, El Qouqa IA. Nosocomial multidrug-resistant Acinetobacter baumannii in the neonatal intensive care unit in Gaza City, Palestine. Int J Infect Dis 2009; 13:623–628 [View Article] [PubMed]
    [Google Scholar]
  46. Wei HM, Hsu YL, Lin HC, Hsieh TH, Yen TY et al. Multidrug-resistant Acinetobacter baumannii infection among neonates in a neonatal intensive care unit at a medical center in central Taiwan. J Microbiol Immunol Infect 2015; 48:531–539 [View Article]
    [Google Scholar]
  47. Mahich S, Angurana SK, Suthar R, Sundaram V, Munda VS et al. Acinetobacter Sepsis among out-born neonates admitted to neonatal unit in pediatric emergency of a tertiary care hospital in North India. Indian J Pediatr 2021; 88:127–133 [View Article] [PubMed]
    [Google Scholar]
  48. Nazir A. Multidrug-resistant Acinetobacter septicemia in neonates: a study from a teaching hospital of Northern India. J Lab Physicians 2019; 11:23–28 [View Article] [PubMed]
    [Google Scholar]
  49. Zhang W, Lei C, Liu J, Yang W, Zhao J et al. Assessing the impact of COVID-19 on the epidemiology of acinetobacter baumannii: a longitudinal study spanning from 2014 to 2023. 28 may 2024, PREPRINT (version 1) available at research square. [View Article]
  50. Vestby LK, Grønseth T, Simm R, Nesse LL. Bacterial biofilm and its role in the pathogenesis of disease. Antibiotics 2020; 9:59 [View Article] [PubMed]
    [Google Scholar]
  51. Mohamed EA, Raafat MM, Samir Mohamed R, Ali AEE. Acinetobacter baumannii biofilm and its potential therapeutic targets. Futur J Pharm Sci 2023; 9:82 [View Article]
    [Google Scholar]
  52. Pour NK, Dusane DH, Dhakephalkar PK, Zamin FR, Zinjarde SS et al. Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol Med Microbiol 2011; 62:328–338 [View Article] [PubMed]
    [Google Scholar]
  53. Greene C, Wu J, Rickard AH, Xi C. Evaluation of the ability of Acinetobacter baumannii to form biofilms on six different biomedical relevant surfaces. Lett Appl Microbiol 2016; 63:233–239 [View Article] [PubMed]
    [Google Scholar]
  54. Alav I, Sutton JM, Rahman KM. Role of bacterial efflux pumps in biofilm formation. J Antimicrob Chemother 2018; 73:2003–2020 [View Article] [PubMed]
    [Google Scholar]
  55. Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E et al. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care 2012; 16:R93 [View Article] [PubMed]
    [Google Scholar]
  56. Feldman C, Kassel M, Cantrell J, Kaka S, Morar R et al. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur Respir J 1999; 13:546–551 [View Article]
    [Google Scholar]
  57. Sottile FD, Marrie TJ, Prough DS, Hobgood CD, Gower DJ et al. Nosocomial pulmonary infection: possible etiologic significance of bacterial adhesion to endotracheal tubes. Crit Care Med 1986; 14:265–270 [View Article] [PubMed]
    [Google Scholar]
  58. Gedefie A, Demsis W, Ashagrie M, Kassa Y, Tesfaye M et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infect Drug Resist 2021; 14:3711–3719 [View Article] [PubMed]
    [Google Scholar]
  59. Reena AAA, Subramaniyan A, Kanungo R. Biofilm formation as a virulence factor of Acinetobacter baumannii: an emerging pathogen in critical care units. J Curr Res 2017; 3:74–78 [View Article]
    [Google Scholar]
  60. Ghannoum M, Parsek M, Whiteley M, Mukherjee PK. Microbial biofilms. In John Wiley & Sons vol 22 2020 p 1142 [View Article]
    [Google Scholar]
  61. Toyofuku M, Inaba T, Kiyokawa T, Obana N, Yawata Y et al. Environmental factors that shape biofilm formation. Biosci Biotechnol Biochem 2016; 80:7–12 [View Article] [PubMed]
    [Google Scholar]
  62. Abd El-Rahman OA, Rasslan F, Hassan SS, Ashour HM, Wasfi R. The RND efflux pump gene expression in the biofilm formation of Acinetobacter baumannii. Antibiotics 2023; 12:419 [View Article] [PubMed]
    [Google Scholar]
  63. Gabor Varga Z, Agnes Szabo M, Schelz Z, Szegedi E, Amaral L. Quorum sensing inhibition by phenothiazines and related compounds. Lett Drug Des Discov 2011; 8:133–137 [View Article]
    [Google Scholar]
  64. Pumbwe L, Skilbeck CA, Wexler HM. Presence of quorum-sensing systems associated with multidrug resistance and biofilm formation in Bacteroides fragilis. Microb Ecol 2008; 56:412–419 [View Article]
    [Google Scholar]
  65. Kaur B, Gupta J, Sharma S, Sharma D, Sharma S. Focused review on dual inhibition of quorum sensing and efflux pumps: a potential way to combat multi drug resistant Staphylococcus aureus infections. Int J Biol Macromol 2021; 190:33–43 [View Article] [PubMed]
    [Google Scholar]
  66. Kurihara MNL, Sales RO, Silva KE da, Maciel WG, Simionatto S. Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings. Rev Soc Bras Med Trop 2020; 53:e20200248 [View Article] [PubMed]
    [Google Scholar]
  67. Nowak J, Seifert H, Higgins PG. Prevalence of eight resistance-nodulation-division efflux pump genes in epidemiologically characterized Acinetobacter baumannii of worldwide origin. J Med Microbiol 2015; 64:630–635 [View Article] [PubMed]
    [Google Scholar]
  68. Kim C-M, Park G, Ko YJ, Kang S-H, Jang SJ. Relationships between relative expression of RND efflux pump genes, H33342 efflux activity, biofilm-forming activity, and antimicrobial resistance in Acinetobacter baumannii clinical isolates. Jpn J Infect Dis 2021; 74:499–506 [View Article] [PubMed]
    [Google Scholar]
  69. Queck SY, Jameson-Lee M, Villaruz AE, Bach T-HL, Khan BA et al. RNAIII-independent target gene control by the agr quorum-sensing system: insight into the evolution of virulence regulation in Staphylococcus aureus. Mol Cell 2008; 32:150–158 [View Article] [PubMed]
    [Google Scholar]
  70. Wang J, Jiao H, Meng J, Qiao M, Du H et al. Baicalin inhibits biofilm formation and the quorum-sensing system by regulating the MsrA drug efflux pump in Staphylococcus saprophyticus. Front Microbiol 2019; 10:2800 [View Article]
    [Google Scholar]
  71. Dawan J, Li Y, Lu F, He X, Ahn J. Role of efflux pump-mediated antibiotic resistance in quorum sensing-regulated biofilm formation by Salmonella Typhimurium. Pathogens 2022; 11:147 [View Article] [PubMed]
    [Google Scholar]
  72. Li Y, Ge X. Role of berberine as a potential efflux pump inhibitor against MdfA from Escherichia coli:in vitro and in Silico studies. Microbiol Spectr 2023; 11:e03324-22 [View Article]
    [Google Scholar]
  73. Piddock LJV. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006; 4:629–636 [View Article] [PubMed]
    [Google Scholar]
  74. Kornelsen V, Kumar A. Update on multidrug resistance efflux pumps in Acinetobacter spp. Antimicrob Agents Chemother 2021; 65:e0051421 [View Article] [PubMed]
    [Google Scholar]
  75. Sharma A, Gupta VK, Pathania R. Efflux pump inhibitors for bacterial pathogens: from bench to bedside. Indian J Med Res 2019; 149:129–145 [View Article]
    [Google Scholar]
  76. Ghalavand Z, Eslami G, Hashemi A, Sadredinamin M, Yousefi N et al. Characterization of sequence types and mechanisms of resistance to tigecycline among Acinetobacter baumannii isolated from children. Curr Microbiol 2022; 79:285 [View Article] [PubMed]
    [Google Scholar]
  77. Luo B, Li Z, Wang Q, Wang C. Synergistic role of biofilm-associated genes and efflux pump genes in tigecycline resistance of Acinetobacter baumannii. Med Sci Monit 2023; 29:e940704 [View Article] [PubMed]
    [Google Scholar]
  78. Jung HW, Kim K, Islam MM, Lee JC, Shin M. Role of ppGpp-regulated efflux genes in Acinetobacter baumannii. J Antimicrob Chemother 2020; 75:1130–1134 [View Article] [PubMed]
    [Google Scholar]
  79. Henry R, Crane B, Powell D, Deveson Lucas D, Li Z et al. The transcriptomic response of Acinetobacter baumannii to colistin and doripenem alone and in combination in an in vitro pharmacokinetics/pharmacodynamics model. J Antimicrob Chemother 2015; 70:1303–1313 [View Article] [PubMed]
    [Google Scholar]
  80. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 2020; 51:79–84 [View Article]
    [Google Scholar]
  81. Shirin AM. Acinetobacter Medication. In Medscape 2023
    [Google Scholar]
  82. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021; 10:373 [View Article] [PubMed]
    [Google Scholar]
  83. Weinberg SE, Villedieu A, Bagdasarian N, Karah N, Teare L et al. Control and management of multidrug resistant Acinetobacter baumannii: a review of the evidence and proposal of novel approaches. Infect Prev Pract 2020; 2:100077 [View Article] [PubMed]
    [Google Scholar]
  84. Hua X, He J, Wang J, Zhang L, Zhang L et al. Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf. Emerg Microbes Infect 2021; 10:1404–1417 [View Article] [PubMed]
    [Google Scholar]
  85. Casarotta E, Bottari E, Vannicola S, Giorgetti R, Domizi R et al. n.d. Antibiotic treatment of Acinetobacter baumannii superinfection in patients with SARS-CoV-2 infection admitted to intensive care unit: an observational retrospective study. Front Med 9:910031 [View Article]
    [Google Scholar]
  86. Schouten G, Paulussen F, Kuipers O, Bitter W, Grossmann T et al. Stapling of peptides potentiates the antibiotic treatment of Acinetobacter baumannii in vivo. Antibiotics 2022; 11:273 [View Article]
    [Google Scholar]
  87. Naafs MAB. The antimicrobial peptides: ready for clinical trials?. Biomed J Sci Tech Res 2018; 7:6038–6043 [View Article]
    [Google Scholar]
  88. Marr AK, Gooderham WJ, Hancock REW. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006; 6:468–472 [View Article] [PubMed]
    [Google Scholar]
  89. de Freitas SB, Hartwig DD. Promising targets for immunotherapeutic approaches against Acinetobacter baumannii. Microbial Pathogenesis 2022; 173:105855 [View Article]
    [Google Scholar]
  90. Altamirano FG, Forsyth JH, Patwa R, Kostoulias X, Trim M et al. Bacteriophages targeting Acinetobacter baumannii capsule induce antimicrobial resensitization. bioRxiv 2020 [View Article]
    [Google Scholar]
  91. Vasudevan A, Kesavan DK, Wu L, Su Z, Wang S et al. In silico and in vitro screening of natural compounds as broad-spectrum β-lactamase inhibitors against Acinetobacter baumannii New Delhi metallo-β-lactamase-1 (NDM-1). Biomed Res Int 2022; 10: [View Article]
    [Google Scholar]
  92. Soto SM. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence 2013; 4:223–229 [View Article]
    [Google Scholar]
  93. Aygül A. The importance of efflux systems in antibiotic resistance and efflux pump inhibitors in the management of resistance. Mikrobiyol Bul 2015; 49:278–291 [View Article]
    [Google Scholar]
  94. Lamers RP, Cavallari JF, Burrows LL. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria. PLoS One 2013; 8:e60666 [View Article] [PubMed]
    [Google Scholar]
  95. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45:105–116 [View Article] [PubMed]
    [Google Scholar]
  96. Ohene-Agyei T, Mowla R, Rahman T, Venter H. Phytochemicals increase the antibacterial activity of antibiotics by acting on a drug efflux pump. Microbiologyopen 2014; 3:885–896 [View Article] [PubMed]
    [Google Scholar]
  97. Ren J, Wang M, Zhou W, Liu Z. Efflux pumps as potential targets for biofilm inhibition. Front Microbiol 2024; 15:1315238 [View Article]
    [Google Scholar]
  98. Vargiu AV, Ruggerone P, Opperman TJ, Nguyen ST, Nikaido H. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrob Agents Chemother 2014; 58:6224–6234 [View Article] [PubMed]
    [Google Scholar]
  99. Bhardwaj KA, Mohanty P. Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvinating the antimicrobial chemotherapy. Recent Pat Antiinfect Drug Discov 2012; 7:73–89 [View Article]
    [Google Scholar]
  100. AlMatar M, Albarri O, Makky EA, Köksal F. Efflux pump inhibitors: new updates. Pharmacol Rep 2021; 73:1–16 [View Article] [PubMed]
    [Google Scholar]
  101. Mehta JY, Jandaik SU. Evaluation of phytochemicals and synergistic interaction between plant extracts and antibiotics for efflux pump inhibitory activity against Salmonella enterica serovar typhimurium strains. Int J Pharm Pharm Sci 2016; 8:217 [View Article]
    [Google Scholar]
  102. Saviuc C, Gheorghe I, Coban S, Drumea V, Chifiriuc MC et al. Rosmarinus officinalis essential oil and eucalyptol act as efflux pumps inhibitors and increase ciprofloxacin efficiency against Pseudomonas aeruginosa and Acinetobacter baumannii MDR strains. Rom Biotechnol Lett 2016; 21:11783 [View Article]
    [Google Scholar]
  103. Compagne N, Vieira Da Cruz A, Müller RT, Hartkoorn RC, Flipo M et al. Update on the discovery of efflux pump inhibitors against critical priority gram-negative bacteria. Antibiotics 2023; 12:180 [View Article] [PubMed]
    [Google Scholar]
  104. Wang Y, Zhang Y, Song X, Fang C, Xing R et al. 1,8-Cineole inhibits biofilm formation and bacterial pathogenicity by suppressing luxS gene expression in Escherichia coli. Front Pharmacol 2022; 13:988245 [View Article] [PubMed]
    [Google Scholar]
  105. Stavri M, Piddock LJV, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007; 59:1247–1260 [View Article] [PubMed]
    [Google Scholar]
  106. Parai D, Banerjee M, Dey P, Mukherjee SK. Reserpine attenuates biofilm formation and virulence of Staphylococcus aureus. Microb Pathog 2020; 138:103790 [View Article] [PubMed]
    [Google Scholar]
  107. Ball AR, Casadei G, Samosorn S, Bremner JB, Ausubel FM et al. Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chem Biol 2006; 1:594–600 [View Article] [PubMed]
    [Google Scholar]
  108. Shokoofeh N, Moradi-Shoeili Z, Naeemi AS, Jalali A, Hedayati M et al. Biosynthesis of Fe3O4@Ag nanocomposite and evaluation of its performance on expression of norA and norB efflux pump genes in ciprofloxacin-resistant Staphylococcus aureus. Biol Trace Elem Res 2019; 191:522–530 [View Article] [PubMed]
    [Google Scholar]
  109. Lei Z, Karim A. The challenges and applications of nanotechnology against bacterial resistance. J Vet Pharmacol Ther 2021; 44:281–297 [View Article] [PubMed]
    [Google Scholar]
  110. Dey N, Kamatchi C, Vickram AS, Anbarasu K, Thanigaivel S et al. Role of nanomaterials in deactivating multiple drug resistance efflux pumps – a review. Environ Res 2022; 204:111968 [View Article]
    [Google Scholar]
  111. Verma A, Bharadvaja N. Plant-mediated synthesis and characterization of silver and copper oxide nanoparticles: antibacterial and heavy metal removal activity. J Clust Sci 2022; 33:1697–1712 [View Article]
    [Google Scholar]
  112. Musiol R. Efflux systems as a target for anti-biofilm nanoparticles: perspectives on emerging applications. Expert Opin Ther Targets 2023; 27:953–963 [View Article]
    [Google Scholar]
  113. Ahmed FY, Aly UF, Abd El-Baky RM, Waly NGFM. Effect of titanium dioxide nanoparticles on the expression of efflux pump and quorum-sensing genes in MDR Pseudomonas aeruginosa isolates. Antibiotics 2021; 10:625 [View Article] [PubMed]
    [Google Scholar]
  114. Pajand O, Rezaee MA, Nahaei MR, Mahdian R, Aghazadeh M et al. Study of the carbapenem resistance mechanisms in clinical isolates of Acinetobacter baumannii: comparison of burn and non-burn strains. Burns 2013; 39:1414–1419 [View Article]
    [Google Scholar]
  115. Uppalapati SR, Sett A, Pathania R. The outer membrane proteins OmpA, CarO, and OprD of Acinetobacter baumannii confer a two-pronged defense in facilitating its success as a potent human pathogen.. Front Microbiol 2020; 11:589234 [View Article]
    [Google Scholar]
  116. Vashist J, Tiwari V, Kapil A, Rajeswari MR. Quantitative profiling and identification of outer membrane proteins of β-lactam resistant strain of Acinetobacter baumannii. . J Proteome Res 2010; 9:1121–1128 [View Article]
    [Google Scholar]
  117. Lee H, Yong D, Yum JH, Roh KH, Lee K et al. Dissemination of 16S rRNA methylase-mediated highly amikacin-resistant isolates of Klebsiella pneumoniae and Acinetobacter baumannii in Korea. Diagn Microbiol Infect Dis 2006; 56:305–312 [View Article]
    [Google Scholar]
  118. Elham B, Fawzia A. Colistin resistance in Acinetobacter baumannii isolated from critically ill patients: clinical characteristics, antimicrobial susceptibility and outcome. Afr Health Sci 2019; 19:2400–2406 [View Article]
    [Google Scholar]
  119. Morel C, Stermitz FR, Tegos G, Lewis K. Isoflavones as potentiators of antibacterial activity. J Agric Food Chem 2003; 51:5677–5679 [View Article] [PubMed]
    [Google Scholar]
  120. Oluwatuyi M, Kaatz GW, Gibbons S. Antibacterial and resistance modifying activity of Rosmarinus officinalis. . Phytochemistry 2004; 65:3249–3254 [View Article] [PubMed]
    [Google Scholar]
  121. Lorenzi V, Muselli A, Bernardini AF, Berti L, Pagès J-M et al. Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species. Antimicrob Agents Chemother 2009; 53:2209–2211 [View Article] [PubMed]
    [Google Scholar]
  122. Pal A, Tripathi A. Quercetin inhibits carbapenemase and efflux pump activities among carbapenem-resistant gram-negative bacteria. APMIS 2020; 128:251–259 [View Article]
    [Google Scholar]
  123. Hazlett LD, Ekanayaka SA, McClellan SA, Francis R. Glycyrrhizin use for multi-drug resistant Pseudomonas aeruginosa: in vitro and in vivo Studies. Invest Ophthalmol Vis Sci 2019; 60:2978–2989 [View Article] [PubMed]
    [Google Scholar]
  124. Tambat R, Mahey N, Chandal N, Verma DK, Jangra M et al. A microbe-derived efflux pump inhibitor of the resistance-nodulation-cell division protein restores antibiotic susceptibility in Escherichia coli and Pseudomonas aeruginosa. ACS Infect Dis 2022; 8:255–270 [View Article] [PubMed]
    [Google Scholar]
  125. Piddock LJV, Garvey MI, Rahman MM, Gibbons S. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in gram-negative bacteria. J Antimicrob Chemother 2010; 65:1215–1223 [View Article] [PubMed]
    [Google Scholar]
  126. Bhardwaj AK, Mohanty P. Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvinating the antimicrobial chemotherapy. Recent Pat Antiinfect Drug Discov 2012; 7:73–89 [View Article] [PubMed]
    [Google Scholar]
  127. Aparna V, Dineshkumar K, Mohanalakshmi N, Velmurugan D, Hopper W. Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation. PLoS One 2014; 9:e101840 [View Article] [PubMed]
    [Google Scholar]
  128. Aghayan SS, Kalalian Mogadam H, Fazli M, Darban-Sarokhalil D, Khoramrooz SS et al. The effects of berberine and palmatine on efflux pumps inhibition with different gene patterns in Pseudomonas aeruginosa isolated from burn infections. Avicenna J Med Biotechnol 2017; 9:2–7 [PubMed]
    [Google Scholar]
  129. Kurinčič M, Klančnik A, Smole Možina S. Effects of efflux pump inhibitors on erythromycin, ciprofloxacin, and tetracycline resistance in Campylobacter spp. isolates. Microb Drug Resist 2012; 18:492–501 [View Article] [PubMed]
    [Google Scholar]
  130. Dwivedi GR, Upadhyay HC, Yadav DK, Singh V, Srivastava SK et al. 4-Hydroxy-α-tetralone and its derivative as drug resistance reversal agents in multi drug resistant Escherichia coli. Chem Biol Drug Des 2014; 83:482–492 [View Article] [PubMed]
    [Google Scholar]
  131. Saleh NM, Ezzat H, El-Sayyad GS, Zedan H. Regulation of overexpressed efflux pump encoding genes by cinnamon oil and trimethoprim to abolish carbapenem-resistant Acinetobacter baumannii clinical strains. BMC Microbiol 2024; 24:52 [View Article] [PubMed]
    [Google Scholar]
  132. Verma P, Tiwari M, Tiwari V. Potentiate the activity of current antibiotics by naringin dihydrochalcone targeting the AdeABC efflux pump of multidrug-resistant Acinetobacter baumannii. Int J Biol Macromol 2022; 217:592–605 [View Article] [PubMed]
    [Google Scholar]
  133. Singkham-In U, Higgins PG, Wannigama DL, Hongsing P, Chatsuwan T. Rescued chlorhexidine activity by resveratrol against carbapenem-resistant Acinetobacter baumannii via down-regulation of AdeB efflux pump. PLoS One 2022; 15:e0272881 [View Article] [PubMed]
    [Google Scholar]
  134. Rana T, Singh S, Kaur K, Pathania K, Farooq U. A review on efflux pump inhibitors of medically important bacteria from plant sources. Int J Pharm Sci Rev Res 2014; 26:101–111
    [Google Scholar]
  135. Dai J, Xu J, Shen H, Chen N, Zhu B et al. The induced and intrinsic resistance of Escherichia coli to sanguinarine is mediated by AcrB efflux pump. Microbiol Spectr 2024; 12:e03237-23 [View Article]
    [Google Scholar]
  136. Gomaa SE, Abbas HA, Mohamed FA, Ali MAM, Ibrahim TM et al. The anti-staphylococcal fusidic acid as an efflux pump inhibitor combined with fluconazole against vaginal candidiasis in mouse model. BMC Microbiol 2024; 24:54 [View Article]
    [Google Scholar]
  137. Kristensen R, Andersen JB, Rybtke M, Jansen CU, Fritz BG et al. Inhibition of Pseudomonas aeruginosa quorum sensing by chemical induction of the MexEF-oprN efflux pump. Antimicrob Agents Chemother 2024; 68:e01387-23 [View Article]
    [Google Scholar]
  138. Plasencia-Rebata S, Levy-Blitchtein S, Del Valle-Mendoza J, Silva-Caso W, Peña-Tuesta I et al. Effect of phenylalanine-arginine beta-naphthylamide on the values of minimum inhibitory concentration of quinolones and aminoglycosides in clinical isolates of Acinetobacter baumannii. Antibiotics 2023; 12:1071 [View Article] [PubMed]
    [Google Scholar]
  139. Lomovskaya O, Zgurskaya HI, Bostian KA, Lewis K. Multidrug efflux pumps: structure, mechanism, and inhibition. In Bacterial Resistance to Antimicrobials 2008 pp 45–69 [View Article]
    [Google Scholar]
  140. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B et al. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58:574–576 [View Article]
    [Google Scholar]
  141. Singh V, Suri JC, Sen MK, Chatterjee T, Haldar D et al. Lung india. Lung India 2011; 28:65 [View Article]
    [Google Scholar]
  142. Bohnert JA, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 2005; 49:849–852 [View Article]
    [Google Scholar]
  143. Becker H, Scher JM, Speakman JB, Zapp J. Bioactivity guided isolation of antimicrobial compounds from Lythrum salicaria. Fitoterapia 2005; 76:580–584 [View Article] [PubMed]
    [Google Scholar]
  144. Miyasaki Y, Rabenstein JD, Rhea J, Crouch M-L, Mocek UM et al. Isolation and characterization of antimicrobial compounds in plant extracts against multidrug-resistant Acinetobacter baumannii. PLoS One 2013; 8:e61594 [View Article]
    [Google Scholar]
  145. Pelletier RP. Effect of plant-derived molecules on Acinetobacter baumannii biofilm on abiotic surfaces. Honors Scholar Theses; 2012 p 257
    [Google Scholar]
  146. Montagu A, Saulnier P, Cassisa V, Rossines E, Eveillard M. Aromatic and terpenic compounds loaded in lipidic nanocapsules: activity against multi-drug resistant Acinetobacter baumannii assessed in vitro and in a murine model of sepsis. J Nanomed Nanotechnol 2014; 5:206 [View Article]
    [Google Scholar]
  147. Johny AK, Hoagland T, Venkitanarayanan K. Effect of subinhibitory concentrations of plant-derived molecules in increasing the sensitivity of multidrug-resistant Salmonella enterica serovar typhimurium DT104 to antibiotics. Foodborne Pathog Dis 2010; 7:1165–1170 [View Article]
    [Google Scholar]
  148. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 2009; 53:1592–1597 [View Article]
    [Google Scholar]
  149. Mun SH, Joung DK, Kim YS, Kang OH, Kim SB et al. Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine 2013; 20:714–718 [View Article]
    [Google Scholar]
  150. Betts JW, Wareham DW. In vitro activity of curcumin in combination with epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii. BMC Microbiol 2014; 14:172 [View Article] [PubMed]
    [Google Scholar]
  151. Osterburg A, Gardner J, Hyon SH, Neely A, Babcock G. Highly antibiotic-resistant Acinetobacter baumannii clinical isolates are killed by the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG). Clin Microbiol Infect 2009; 15:341–346 [View Article]
    [Google Scholar]
  152. Betts JW, Kelly SM, Haswell SJ. Antibacterial effects of theaflavin and synergy with epicatechin against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. Int J Antimicrob Agents 2011; 38:421–425 [View Article]
    [Google Scholar]
  153. Chan BC, Lau CB, Jolivalt C, Lui SL, Ganem-Elbaz C et al. Chinese medicinal herbs against antibiotic-resistant bacterial pathogens. Science Against Microbial Pathogens 2011; 2:773–781
    [Google Scholar]
  154. Tiwari V, Roy R, Tiwari M. Antimicrobial active herbal compounds against Acinetobacter baumannii and other pathogens. Front Microbiol 2015; 6:618 [View Article]
    [Google Scholar]
  155. Jadimurthy R, Jagadish S, Nayak SC, Kumar S, Mohan CD et al. Phytochemicals as invaluable sources of potent antimicrobial agents to combat antibiotic resistance. Life 2023; 13:948 [View Article]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001867
Loading
/content/journal/jmm/10.1099/jmm.0.001867
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error